Ritu Salani MD

Ritu Salani MD
Assoc ProfessorCollege of Medicinesalani.2@osu.edu
SLM 210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7642Fax: 614-293-9078
  • Cancer Control

Research Description

Dr. Salani's interests include surgery for advanced ovarian cancer, healthcare quality, outcome analysis and optimizing healthcare service delivery.

Current Publications

  • Salani R, Billingsley CC, Crafton SMReply.Am J Obstet Gynecol 211 83 7/1/2014
  • Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJA phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.Gynecol Oncol in press 6/5/2014
  • Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer ELFeasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.Int J Gynecol Cancer 24 682-6 5/1/2014
  • Liang MI, Rosen MA, Rath KS, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DEReducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.Gynecol Oncol 131 508-11 12/1/2013
  • Salani RSurvivorship planning in gynecologic cancer patients.Gynecol Oncol 130 389-97 8/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23 833-8 6/1/2013
  • Brothers BM, Easley A, Salani R, Andersen BLDo survivorship care plans impact patients' evaluations of care? A randomized evaluation with gynecologic oncology patients.Gynecol Oncol 129 554-8 6/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129 135-9 4/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129 103-6 4/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128 44-8 1/1/2013
  • Tiwari P, Coriddi M, Salani R, Povoski SPBreast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options.World J Surg Oncol 11 237 1/1/2013
  • McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler JM, Cohn DE, O'Malley DMRecurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Gynecol Oncol 127 362-6 11/1/2012
  • Salani R, O'Malley DMHere it comes....the role of cost-effective analysis.Gynecol Oncol 127 265-6 11/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu